Gilead to Present Twice-Yearly HIV Data at AIDS 2026
• Gilead Sciences will present clinical data for its HIV pre-exposure prophylaxis (PrEP) drug, lenacapavir, at the AIDS 2026 conference from July 26-31. • The data reveals high efficacy in two studies: PURPOSE 1 recorded zero new HIV infections, while PURPOSE 2 reported only one infection among participants continuing the treatment. • These results are significant as they support the development of a twice-yearly dosing schedule, potentially increasing patient adherence and expanding the preventive drug market.
stocktitan.net